SCHEMBL313506

SCHEMBL313506

Fc1ccc(F)c(Br)c1F

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
GPR84 Q9NQS5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1426701 0.82 CYP2A6 (0.33)
SCHEMBL246708 0.81 CES2 (0.39) CES2CES1GPR84
SCHEMBL1770614 0.81 KDM1A (0.35)
SCHEMBL30906668 0.77
SCHEMBL5019963 0.77 CA3 (0.39) CES2CES1
SCHEMBL8979083 0.77
SCHEMBL4623500 0.77 ACHE (0.36)
SCHEMBL11131552 0.77 TP53 (0.32) CES2CES1
SCHEMBL31035242 0.77 CES2 (0.31) CES2CES1
SCHEMBL5730841 0.77 ALDH1A1 (0.39) CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543319-A1 METHOD OF MARKING HYDROCARBON LIQUIDS Johnson Matthey Public Limited Company (GB) 2019-09-25 EP claimed
US-20140120626-A1 METHOD OF MARKING HYDROCARBON LIQUIDS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2014-05-01 US claimed
EP-2707465-A1 METHOD OF MARKING HYDROCARBON LIQUIDS Johnson Matthey Public Limited Company (GB) 2014-03-19 EP claimed
WO-2012153132-A1 METHOD OF MARKING HYDROCARBON LIQUIDS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-11-15 WO claimed
EP-0667328-B1 Process for the preparation of aromatic fluoro compounds CLARIANT GMBH (DE) 1998-09-16 EP claimed
US-5498807-A Process for the preparation of aromatic fluoro compounds HOECHST AKTIENGESELLSCHAFT (DE) 1996-03-12 US claimed
EP-0667328-A1 Process for the preparation of aromatic fluoro compounds HOECHST AKTIENGESELLSCHAFT (DE) 1995-08-16 EP claimed
US-12577245-B2 Sulfonyl benzamide derivatives as Bcl-2 inhibitors ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2026-03-17 US disclosed
US-12552767-B2 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists MERCK SHARP & DOHME LLC (US) 2026-02-17 US disclosed
US-20260001843-A1 SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2026-01-01 US disclosed
US-12406696-B2 Photopolymer compositions for thermostable photopolymers in the visible spectral range COVESTRO DEUTSCHLAND AG (DE) 2025-09-02 US disclosed
US-12351565-B2 Aromatic compound and preparation method therefor and use thereof SHANGHAI ZHIGEN PHARMACEUTICAL & TECHNOLOGY CO., LTD. (CN) 2025-07-08 US disclosed
US-20250182787-A1 Photopolymer Compositions for Thermostable Photopolymers in the Visible Spectral Range COVESTRO DEUTSCHLAND AG (DE) 2025-06-05 US disclosed
EP-0667328-B1 Process for the preparation of aromatic fluoro compounds CLARIANT GMBH (DE) 1998-09-16 EP disclosed
US-5498807-A Process for the preparation of aromatic fluoro compounds HOECHST AKTIENGESELLSCHAFT (DE) 1996-03-12 US disclosed
EP-0667328-A1 Process for the preparation of aromatic fluoro compounds HOECHST AKTIENGESELLSCHAFT (DE) 1995-08-16 EP disclosed
US-4593047-A Alcoholism RICHTER GEDEON VEGYESZETI CYAR RT (HU) 1986-06-03 US disclosed
EP-0109606-B1 PROCESS FOR THE FORMYLATION OF ARYL HALIDES BAYER AG (DE) 1986-01-22 EP disclosed
US-4536344-A USING A PHOSPINE OR PHOSPHITE BAYER AKTIENGESELLSCHAFT (DE) 1985-08-20 US disclosed
EP-0109606-A1 Process for the formylation of aryl halides BAYER AG (DE) 1984-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577245-B2 Sulfonyl benzamide derivatives as Bcl-2 inhibitors BCL2A1, BCL2L1, BCL2L11 CES2 690/4885CES1 649/4885GPR84 2383/4885
US-12351565-B2 Aromatic compound and preparation method therefor and use thereof CYP4F11, PAH, COMT CES2 2251/4885CES1 1788/4885GPR84 2867/4885
US-12552767-B2 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists HCRTR2, HCRTR1, NPY1R CES2 1507/4885CES1 1161/4885GPR84 159/4885
US-20260001843-A1 SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF HCRTR2, HCRTR1, NPBWR1 CES2 1136/4885CES1 1677/4885GPR84 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.